Loading clinical trials...
Loading clinical trials...
A PHASE 2B RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY PROFILE OF PF-06651600 WITH A PARTIALLY BLINDED EXTENSION PERIOD TO EVALUATE THE EFFICACY AND SAFETY OF PF-06651600 AND PF-06700841 IN SUBJECTS WITH ACTIVE NON-SEGMENTAL VITILIGO
Conditions
Interventions
PF-06651600
PF-06651600
+6 more
Locations
92
United States
Marvel Research, LLC
Huntington Beach, California, United States
University of California, Irvine, Dermatology Clinical Research Center
Irvine, California, United States
Vitiligo and Pigmentation Institute Of Southern California
Los Angeles, California, United States
Dermatology Specialist, Inc.
Murrieta, California, United States
Dermatology Specialists, Inc.
Oceanside, California, United States
UC Davis Health
Sacramento, California, United States
Start Date
November 26, 2018
Primary Completion Date
February 5, 2021
Completion Date
February 5, 2021
Last Updated
March 25, 2022
Lead Sponsor
Pfizer
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions